Iovance Biotherapeutics: Amtagvi Boom Drives Forecast!

The surprisingly strong market demand for the cancer therapies Amtagvi (Lifileucel) and Proleukin is leading to a drastic increase in the annual forecast. With its groundbreaking TIL therapy, the company is addressing the growing oncology market and expanding its clinical pipelines for other solid tumors. Despite a weak overall market, investors are massively accumulating shares, indicating real company-specific momentum and high intrinsic strength. Iovance Biotherapeutics has established itself as a pioneer in the development of innovative...